Dennis A Hesselink

List of Publications by Year in Descending Order

135 papers	3,649 citations	30 h-index	56 g-index
147 ext. papers	4,603 ext. citations	4.6 avg, IF	5.41 L-index

#	Paper	IF	Citations
135	Immune Subsets From Ficoll Density Gradient Separation in Kidney Transplant Recipients.. *Transplantation Direct*, **2022**, 8, e1319	2.3	0
134	A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients.. *European Journal of Drug Metabolism and Pharmacokinetics*, **2022**, 1	2.7	0
133	Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients.. *European Journal of Clinical Pharmacology*, **2022**, 1	2.8	
132	Monitoring Intracellular Tacrolimus Concentrations And Its Relationship With Rejection In The Early Phase After Renal Transplantation. *Clinical Biochemistry*, **2021**,	3.5	1
131	Development and Validation of Hematocrit Level Measurement in Dried Blood Spots Using Near-Infrared Spectroscopy. *Therapeutic Drug Monitoring*, **2021**, 43, 351-357	3.2	3
130	Iron deficiency after kidney transplantation. *Nephrology Dialysis Transplantation*, **2021**, 36, 1976-1985	4.3	3
129	A 2020 Banff Antibody-mediatedInjury Working Group examination of international practices for diagnosing antibody-mediated rejection in kidney transplantation - a cohort study. *Transplant International*, **2021**, 34, 488-498	3	5
128	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. *Therapeutic Drug Monitoring*, **2021**, 43, 150-200	3.2	17
127	Circulating endothelial cells transiently increase in peripheral blood after kidney transplantation. *Scientific Reports*, **2021**, 11, 8915	4.9	0
126	Delayed graft function and rejection are risk factors for cytomegalovirus breakthrough infection in kidney transplant recipients. *Pharmacological Research*, **2021**, 167, 105565	10.2	0
125	Cholesterol Embolization Syndrome After Kidney Transplantation: A Case Series and Systematic Review. *Transplantation Direct*, **2021**, 7, e717	2.3	
124	Pre-transplant donor-reactive IL-21 producing T cells as a tool to identify an increased risk for acute rejection. *Scientific Reports*, **2021**, 11, 12445	4.9	2
123	Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2021**, 54-55, 101756	2.5	1
122	Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients. *BMC Nephrology*, **2021**, 22, 208	2.7	0
121	Pitfalls in the Detection of Donor-Derived Cell-Free DNA in Transplant Recipients. *Clinical Chemistry* , **2021**, 67, 1030-1032	5.5	1
120	A systematic review and meta-analysis of enzyme-linked immunosorbent spot (ELISPOT) assay for BK polyomavirus immune response monitoring after kidney transplantation. *Journal of Clinical Virology*, **2021**, 140, 104848	14.5	1
119	Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients. *British Journal of Clinical Pharmacology*, **2021**, 87, 1918-1929	3.8	6

118	Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection. *Journal of Viral Hepatitis*, **2021**, 28, 431-435	3.4	4
117	Advanced Research Models to Study the Role of Endothelial Cells in Solid Organ Transplantation. *Frontiers in Immunology*, **2021**, 12, 607953	8.4	1
116	Circulating cell-free nucleosomes as biomarker for kidney transplant rejection: a pilot study. *Clinical Epigenetics*, **2021**, 13, 32	7.7	0
115	Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 169-178	6.1	7
114	Care for the organ transplant recipient on the intensive care unit. *Journal of Critical Care*, **2021**, 64, 37-44		
113	Implementation of donation after circulatory death kidney transplantation can safely enlarge the donor pool: A systematic review and meta-analysis. *International Journal of Surgery*, **2021**, 92, 106021	7.5	3
112	Donor-specific ELISPOT assay for predicting acute rejection and allograft function after kidney transplantation: A systematic review and meta-analysis. *Clinical Biochemistry*, **2021**, 94, 1-11	3.5	1
111	A comparison of two different analytical methods for donor-derived cell-free DNA quantification. *Clinical Biochemistry*, **2021**, 96, 82-84	3.5	
110	A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients.. *Clinical and Translational Science*, **2021**,	4.9	2
109	Molecular Analysis of Renal Allograft Biopsies: Where Do We Stand and Where Are We Going?. *Transplantation*, **2020**, 104, 2478-2486	1.8	5
108	COVID-19 in solid organ transplant recipients: a single-center experience. *Transplant International*, **2020**, 33, 1099-1105	3	56
107	Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection. *Frontiers in Immunology*, **2020**, 11, 1332	8.4	3
106	Incidence of end-stage renal disease after heart transplantation and effect of its treatment on survival. *ESC Heart Failure*, **2020**, 7, 533-541	3.7	11
105	Serum magnesium, hepatocyte nuclear factor 1β genotype and post-transplant diabetes mellitus: a prospective study. *Nephrology Dialysis Transplantation*, **2020**, 35, 176-183	4.3	2
104	Protein and calorie restriction may improve outcomes in living kidney donors and kidney transplant recipients. *Aging*, **2020**, 12, 12441-12467	5.6	8
103	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. *Therapeutic Drug Monitoring*, **2020**, 42, 360-368	3.2	25
102	A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement. *Clinical Pharmacokinetics*, **2020**, 59, 591-603	6.2	9
101	Costimulation Blockade in Kidney Transplant Recipients. *Drugs*, **2020**, 80, 33-46	12.1	13

100	Clinical Relevance of Arteriolar C4d Staining in Patients With Chronic-active Antibody-mediated Rejection: A Pilot Study. *Transplantation*, **2020**, 104, 1085-1094	1.8	
99	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. *Therapeutic Drug Monitoring*, **2020**, 42, 665-670	3.2	6
98	Donor-derived cell-free DNA as a biomarker for rejection after kidney transplantation: a systematic review and meta-analysis. *Transplant International*, **2020**, 33, 1626-1642	3	13
97	Acquired haemophilia A after alemtuzumab therapy. *Haemophilia*, **2020**, 26, e337-e339	3.3	2
96	Usage of Tacrolimus and Mycophenolic Acid During Conception, Pregnancy, and Lactation, and Its Implications for Therapeutic Drug Monitoring: A Systematic Critical Review. *Therapeutic Drug Monitoring*, **2020**, 42, 518-531	3.2	12
95	Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients. *Frontiers in Immunology*, **2020**, 11, 1972	8.4	7
94	Utility of immunohistochemistry with C3d in C3 glomerulopathy. *Modern Pathology*, **2020**, 33, 431-439	9.8	3
93	Guillain-Barr□syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	5
92	Oxalate deposition in renal allograft biopsies within 3 months after transplantation is associated with allograft dysfunction. *PLoS ONE*, **2019**, 14, e0214940	3.7	2
91	Exploring the neuroregenerative potential of tacrolimus. *Expert Review of Clinical Pharmacology*, **2019**, 12, 1047-1057	3.8	13
90	The Number of Donor-Specific IL-21 Producing Cells Before and After Transplantation Predicts Kidney Graft Rejection. *Frontiers in Immunology*, **2019**, 10, 748	8.4	18
89	Characterization of donor and recipient CD8+ tissue-resident memory T cells in transplant nephrectomies. *Scientific Reports*, **2019**, 9, 5984	4.9	23
88	Parathyroidectomy versus cinacalcet for tertiary hyperparathyroidism; a retrospective analysis. *Langenbeck's Archives of Surgery*, **2019**, 404, 71-79	3.4	12
87	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. *Transplantation Reviews*, **2019**, 33, 191-199	3.3	5
86	Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of anti-HLA donor-specific antibodies in kidney transplant recipients. *Expert Review of Clinical Immunology*, **2019**, 15, 1323-1331	5.1	10
85	Surgical Safety and Efficacy of Third Kidney Transplantation in the Ipsilateral Iliac Fossa. *Annals of Transplantation*, **2019**, 24, 132-138	1.4	6
84	Targeted Proteomic Analysis Detects Acute T Cell-Mediated Kidney Allograft Rejection in Belatacept-Treated Patients. *Therapeutic Drug Monitoring*, **2019**, 41, 243-248	3.2	1
83	High Intrapatient Variability in Tacrolimus Exposure Is Not Associated With Immune-mediated Graft Injury After Liver Transplantation. *Transplantation*, **2019**, 103, 2329-2337	1.8	6

82	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. *Therapeutic Drug Monitoring*, **2019**, 41, 261-307	3.2	163
81	Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients. *Transplantation Direct*, **2019**, 5, e418	2.3	11
80	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. *British Journal of Clinical Pharmacology*, **2019**, 85, 601-615	3.8	31
79	Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry. *Biomedical Chromatography*, **2019**, 33, e4416	1.7	12
78	Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype. *Pharmacogenomics*, **2018**, 19, 305-310	2.6	3
77	Dosing ribavirin in hepatitis E-infected solid organ transplant recipients. *Pharmacological Research*, **2018**, 130, 308-315	10.2	8
76	Preoperative right heart hemodynamics predict postoperative acute kidney injury after heart transplantation. *Intensive Care Medicine*, **2018**, 44, 588-597	14.5	25
75	Characterization of ectopic lymphoid structures in different types of acute renal allograft rejection. *Clinical and Experimental Immunology*, **2018**, 192, 224-232	6.2	23
74	Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms. *Transplantation Direct*, **2018**, 4, e350	2.3	5
73	Personalized immunosuppression in elderly renal transplant recipients. *Pharmacological Research*, **2018**, 130, 303-307	10.2	17
72	A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. *Clinical Pharmacokinetics*, **2018**, 57, 475-489	6.2	36
71	Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. *Clinical Pharmacokinetics*, **2018**, 57, 191-207	6.2	41
70	Pre-operative proteinuria in left ventricular assist devices and clinical outcome. *Journal of Heart and Lung Transplantation*, **2018**, 37, 124-130	5.8	12
69	Co-inhibitory profile and cytotoxicity of CD57 PD-1 T cells in end-stage renal disease patients. *Clinical and Experimental Immunology*, **2018**, 191, 363-372	6.2	3
68	Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients. *PLoS ONE*, **2018**, 13, e0201113	3.7	7
67	Response: Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. *Frontiers in Immunology*, **2018**, 9, 466	8.4	
66	CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation. *Pharmacogenomics*, **2018**, 19, 895-903	2.6	5
65	Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. *PLoS ONE*, **2018**, 13, e0196552	3.7	20

64	The Efficacy of Rabbit Anti-Thymocyte Globulin for Acute Kidney Transplant Rejection in Patients Using Calcineurin Inhibitor and Mycophenolate Mofetil-Based Immunosuppressive Therapy. *Annals of Transplantation*, **2018**, 23, 577-590	1.4	2
63	Progress of Immunosuppressive regimen after kidney transplantation. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, SY52-1	0	
62	Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. *Clinical Pharmacokinetics*, **2018**, 57, 877-893	6.2	16
61	Acute kidney injury and 1-year mortality after left ventricular assist device implantation. *Journal of Heart and Lung Transplantation*, **2018**, 37, 116-123	5.8	20
60	Liquid Biopsies to Monitor Solid Organ Transplant Function: A Review of New Biomarkers. *Therapeutic Drug Monitoring*, **2018**, 40, 515-525	3.2	23
59	Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. *American Journal of Kidney Diseases*, **2017**, 69, 796-804	7.4	32
58	Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. *British Journal of Surgery*, **2017**, 104, 804-813	5.3	33
57	A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. *Clinical Pharmacokinetics*, **2017**, 56, 963-975	6.2	46
56	The Effect of Tacrolimus and Mycophenolic Acid on CD14+ Monocyte Activation and Function. *PLoS ONE*, **2017**, 12, e0170806	3.7	24
55	Effect of Age and Renal Function on Survival After Left Ventricular Assist Device Implantation. *American Journal of Cardiology*, **2017**, 120, 2221-2225	3	11
54	The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. *Pharmacogenetics and Genomics*, **2017**, 27, 313-322	1.9	33
53	Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial. *Scientific Reports*, **2017**, 7, 15135	4.9	8
52	Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. *Expert Opinion on Drug Metabolism and Toxicology*, **2017**, 13, 1225-1236	5.5	69
51	The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. *British Journal of Clinical Pharmacology*, **2017**, 83, 812-822	3.8	20
50	Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose. *Transplantation Direct*, **2017**, 3, e129	2.3	19
49	Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. *Frontiers in Pharmacology*, **2017**, 8, 358	5.6	29
48	Targeting the Monocyte-Macrophage Lineage in Solid Organ Transplantation. *Frontiers in Immunology*, **2017**, 8, 153	8.4	36
47	Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. *Frontiers in Immunology*, **2017**, 8, 641	8.4	20

46	Neutrophil gelatinase-associated lipocalin (NGAL) predicts the occurrence of malaria-induced acute kidney injury. *Malaria Journal*, **2016**, 15, 464	3.6	15
45	Consideration of the ethnic prevalence of genotypes in the clinical use of tacrolimus. *Pharmacogenomics*, **2016**, 17, 1737-1740	2.6	20
44	Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs. *Therapeutic Drug Monitoring*, **2016**, 38 Suppl 1, S57-69	3.2	39
43	Uremia-Associated Premature Aging of T Cells Does Not Predict Infectious Complications After Renal Transplantation. *American Journal of Transplantation*, **2016**, 16, 2324-33	8.7	7
42	Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 555-65	5.5	86
41	Lung Transplantation in Gaucher Disease: A Learning Lesson in Trying to Avoid Both Scylla and Charybdis. *Chest*, **2016**, 149, e1-5	5.3	14
40	Hepatitis E virus genotype 3 infection in a tertiary referral center in the Netherlands: Clinical relevance and impact on patient morbidity. *Journal of Clinical Virology*, **2016**, 74, 82-7	14.5	14
39	Loss of CD28 on Peripheral T Cells Decreases the Risk for Early Acute Rejection after Kidney Transplantation. *PLoS ONE*, **2016**, 11, e0150826	3.7	26
38	Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells. *PLoS ONE*, **2016**, 11, e0148604	3.7	21
37	Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness. *Transplantation Direct*, **2016**, 2, e83	2.3	7
36	A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. *American Journal of Transplantation*, **2016**, 16, 2085-96	8.7	92
35	A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. *Transplant International*, **2016**, 29, 1158-1167	3	74
34	Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation. *Clinical Epigenetics*, **2016**, 8, 116	7.7	12
33	Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients. *Transplantation Reviews*, **2015**, 29, 224-30	3.3	17
32	Improved long-term survival in Dutch heart transplant patients despite increasing donor age: the Rotterdam experience. *Transplant International*, **2015**, 28, 962-71	3	30
31	Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. *Expert Opinion on Drug Metabolism and Toxicology*, **2015**, 11, 921-36	5.5	23
30	When a zero mismatch is no longer superior. *Transplant International*, **2015**, 28, 398-400	3	
29	Acute kidney injury in imported Plasmodium falciparum malaria. *Malaria Journal*, **2015**, 14, 523	3.6	30

28	Primary Cytomegalovirus Infection Significantly Impacts Circulating T Cells in Kidney Transplant Recipients. *American Journal of Transplantation*, **2015**, 15, 3143-56	8.7	25
27	Renal transplantation in 2014: renal transplantation-reducing risk and improving outcome. *Nature Reviews Nephrology*, **2015**, 11, 72-3	14.9	2
26	Fifteen-year survival of a polycystic kidney transplant. *Transplant International*, **2015**, 28, 870-1	3	1
25	Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. *Transplantation Reviews*, **2015**, 29, 78-84	3.3	111
24	The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. *Clinical Pharmacokinetics*, **2014**, 53, 123-39	6.2	150
23	Practicability of pharmacogenetics in transplantation medicine. *Clinical Pharmacology and Therapeutics*, **2014**, 95, 262-4	6.1	12
22	Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. *Nature Reviews Nephrology*, **2014**, 10, 725-31	14.9	62
21	Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2014**, 945-946, 171-7	3.2	16
20	Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(). *American Journal of Transplantation*, **2013**, 13, 1253-61	8.7	90
19	Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. *Therapeutic Drug Monitoring*, **2013**, 35, 459-65	3.2	32
18	Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. *Therapeutic Drug Monitoring*, **2013**, 35, 617-23	3.2	24
17	Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (. *Therapeutic Drug Monitoring*, **2011**, 33, 688-93	3.2	13
16	The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. *Therapeutic Drug Monitoring*, **2010**, 32, 387-93	3.2	53
15	A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. *Pharmacogenomics*, **2008**, 9, 783-9	2.6	12
14	CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. *Pharmacogenetics and Genomics*, **2008**, 18, 339-48	1.9	96
13	The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. *Nephrology Dialysis Transplantation*, **2005**, 20, 1868-73	4.3	44
12	Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. *Clinical Pharmacology and Therapeutics*, **2005**, 78, 317-21	6.1	54
11	The effects of renal transplantation on circulating dendritic cells. *Clinical and Experimental Immunology*, **2005**, 140, 384-93	6.2	29

10	Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. *American Journal of Transplantation*, **2005**, 5, 987-94	8.7	259
9	The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?. *Pharmacogenomics*, **2005**, 6, 323-37	2.6	76
8	The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy. *Transplant International*, **2004**, 17, 495-504	3	5
7	Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. *Clinical Pharmacology and Therapeutics*, **2004**, 76, 545-56	6.1	128
6	The use of cyclosporine in renal transplantation. *Transplantation Proceedings*, **2004**, 36, 99S-106S	1.1	20
5	Experience with cyclosporine in endogenous uveitis posterior. *Transplantation Proceedings*, **2004**, 36, 372S-377S	1.1	17
4	The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy. *Transplant International*, **2004**, 17, 495-504	3	
3	Profiles of the acute-phase reactants C-reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus. *Scandinavian Journal of Rheumatology*, **2003**, 32, 151-5	1.9	24
2	Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. *Clinical Pharmacology and Therapeutics*, **2003**, 74, 245-54	6.1	501
1	Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. *British Journal of Clinical Pharmacology*, **2003**, 56, 327-30	3.8	58